| 4 | ASO Visual Abstract: CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/ nab-Paclitaxel for Patients with Operable Pancreatic Cancer. (Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S) Ann Surg Oncol 2023 May;30(5):3022 |
| 4 | CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. (Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S) Ann Surg Oncol 2023 May;30(5):3013-3021 |
| 2 | Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. (Hall WA, Evans DB, Tsai S) JAMA Oncol 2023 Feb 01;9(2):275-276 |
| 3 | A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma. (Saif A, Verbus E, Erickson B, Kamgar M, Tsai S, Evans D, Hernandez JM, Hall WA) Ann Surg Oncol 2023 Feb;30(2):688-690 |
| 1 | A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials. (Chrabaszcz S, Rajeev R, Witmer HDD, Dhiman A, Klooster B, Gamblin TC, Banerjee A, Johnston FM, Turaga KK) Am J Clin Oncol 2022 Aug 01;45(8):366-372 |
| 1 | SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. (Botta GP, Kato S, Patel H, Fanta P, Lee S, Okamura R, Kurzrock R) JCI Insight 2021 Sep 22;6(18) 18 Citations |
| 1 | Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. (Rahma OE, Yothers G, Hong TS, Russell MM, You YN, Parker W, Jacobs SA, Colangelo LH, Lucas PC, Gollub MJ, Hall WA, Kachnic LA, Vijayvergia N, O'Rourke MA, Faller BA, Valicenti RK, Schefter TE, George S, Kainthla R, Stella PJ, Sigurdson E, Wolmark N, George TJ) JAMA Oncol 2021 Aug 01;7(8):1225-1230 45 Citations |
| 2 | Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective. (Ward EP, Evans DB, Tsai S) J Surg Oncol 2021 May;123(6):1405-1413 2 Citations |
| 8 | Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. (Barnes CA, Aldakkak M, Christians KK, Clarke CN, Dua K, George B, Ritch PS, Kamgar M, Hall WA, Kulkarni N, Erickson BA, Evans DB, Tsai S) Surgery 2020 Sep;168(3):440-447 11 Citations |
| 1 | What is causing this patient's severe pruritus? (Probst EA, Smith AL, Abad JD) JAAPA 2020 Jun;33(6):54-56 |
| 1 | PTPσ inhibitors promote hematopoietic stem cell regeneration. (Zhang Y, Roos M, Himburg H, Termini CM, Quarmyne M, Li M, Zhao L, Kan J, Fang T, Yan X, Pohl K, Diers E, Jin Gim H, Damoiseaux R, Whitelegge J, McBride W, Jung ME, Chute JP) Nat Commun 2019 Aug 14;10(1):3667 18 Citations |
| 1 | Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. (Macedo FI, Ryon E, Maithel SK, Lee RM, Kooby DA, Fields RC, Hawkins WG, Williams G, Maduekwe U, Kim HJ, Ahmad SA, Patel SH, Abbott DE, Schwartz P, Weber SM, Scoggins CR, Martin RCG, Dudeja V, Franceschi D, Livingstone AS, Merchant NB) Ann Surg 2019 Sep;270(3):400-413 91 Citations |
| 1 | Molecular Mechanism of Inhibition of Acid Ceramidase by Carmofur. (Dementiev A, Joachimiak A, Nguyen H, Gorelik A, Illes K, Shabani S, Gelsomino M, Ahn EE, Nagar B, Doan N) J Med Chem 2019 Jan 24;62(2):987-992 34 Citations |
| 1 | A pediatric case of squamous cell cancer in situ in the setting of sclerodermatous graft-versus-host disease and voriconazole treatment. (Li AW, Lalor LE, Bellodi Schmidt F, Luu M) Pediatr Dermatol 2018 May;35(3):e165-e169 3 Citations |
| 1 | Thymidylate Limitation Potentiates Cephalosporin Activity toward Enterococci via an Exopolysaccharide-Based Mechanism. (Hoff JS, Kristich CJ) ACS Chem Biol 2016 Jun 17;11(6):1561-8 8 Citations |
| 1 | Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. (Martin RC 2nd, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, Kelly LR, Garcia-Monaco RD, Sharma VR, Crocenzi TS, Strasberg SM) Cancer 2015 Oct 15;121(20):3649-58 101 Citations |
| 2 | Neoadjuvant therapy for localized pancreatic cancer: support is growing? (Evans DB, Ritch PS, Erickson BA) Ann Surg 2015 Jan;261(1):18-20 18 Citations |
| 1 | Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. (Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA, SIRFLOX Study Group) BMC Cancer 2014 Dec 01;14:897 49 Citations |
| 2 | Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. (Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2015 Jan 01;91(1):116-23 29 Citations |
| 1 | A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. (Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM) BMC Cancer 2014 Aug 02;14:561 12 Citations |
| 5 | Molecular profiling in gastric cancer: examining potential targets for chemotherapy. (Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC) J Surg Oncol 2014 Sep;110(3):302-6 9 Citations |
| 7 | Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? (Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B) Oncologist 2014 Mar;19(3):266-74 160 Citations |
| 1 | Irinotecan-induced immune thrombocytopenia. (Mirtsching BC, George JN, Aster RH, Curtis BR) Am J Med Sci 2014 Feb;347(2):167-9 4 Citations |
| 1 | Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. (Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB, Katz MH) J Gastrointest Surg 2014 Jan;18(1):16-24; discussion 24-5 152 Citations |
| 1 | Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. (Myklebust MP, Li Z, Tran TH, Rui H, Knudsen ES, Elsaleh H, Fluge Ø, Vonen B, Myrvold HE, Leh S, Tveit KM, Pestell RG, Dahl O) Br J Cancer 2012 Nov 06;107(10):1684-91 21 Citations |
| 3 | Novel multimodality treatment sequencing for extrahepatic (mid and distal) cholangiocarcinoma. (Turaga KK, Tsai S, Wiebe LA, Evans DB, Gamblin TC) Ann Surg Oncol 2013 Apr;20(4):1230-9 9 Citations |
| 1 | Systemic toxicity from occlusive therapy with topical 5-fluorouracil: a case report and review of the literature. (Sargen M, Wanat KA, Jambusaria A, Rosenbach M, Sobanko J, Miller CJ) Dermatol Surg 2012 Oct;38(10):1756-9 8 Citations |
| 1 | Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. (Parsons HA, Tsimberidou AM, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R) Nutr Cancer 2012;64(2):206-17 29 Citations |
| 1 | An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. (Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ) Cancer Cell 2011 Sep 13;20(3):384-99 88 Citations |
| 2 | Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. (Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2012 Mar 15;82(4):1367-75 60 Citations |
| 1 | Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial. (Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, Pisters PW) Ann Surg Oncol 2011 Dec;18(13):3615-22 18 Citations |
| 1 | How does TPF improve survival over PF? (Devisetty K, Wong SJ, Mell LK) Lancet Oncol 2011 May;12(5):419-20; author reply 421-2 3 Citations |
| 1 | Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. (Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R) Clin Colorectal Cancer 2010 Dec;9(5):311-4 |
| 1 | A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. (Lubner SJ, Loconte NK, Holen KD, Schelman W, Thomas JP, Jumonville A, Eickhoff JC, Seo S, Mulkerin DL) Clin Colorectal Cancer 2010 Jul;9(3):157-61 6 Citations |
| 1 | A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. (Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R) Cancer 2010 Sep 01;116(17):4086-94 27 Citations |
| 2 | Management of borderline resectable pancreatic cancer. (Lal A, Christians K, Evans DB) Surg Oncol Clin N Am 2010 Apr;19(2):359-70 9 Citations |
| 1 | Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. (Das P, Delclos ME, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Bedi M, Krishnan S, Crane CH) Int J Radiat Oncol Biol Phys 2010 May 01;77(1):60-5 86 Citations |
| 1 | A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies. (Bekaii-Saab T, Hill M, Campbell A, Kosuri K, Thomas J, Villalona-Calero M) Cancer Chemother Pharmacol 2010 Apr;65(5):863-9 |
| 1 | The integration of chemoradiation in the care of patient with localized pancreatic cancer. (Crane CH, Varadhachary G, Settle SH, Fleming JB, Evans DB, Wolff RA) Cancer Radiother 2009 Apr;13(2):123-43 15 Citations |
| 1 | A phase I study of an oral simulated FOLFOX with high dose capecitabine. (Mulkerin D, LoConte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G) Invest New Drugs 2009 Oct;27(5):461-8 7 Citations |
| 1 | Cisplatin, fluorouracil, interferon-alpha, and radiation as adjuvant therapy for resected pancreatic cancer: is there a future for this regimen and/or should we change our approach to research and treatment of patients with pancreatic cancer? (Pisters PW, Evans DB) Ann Surg 2008 Aug;248(2):152-3 4 Citations |
| 1 | Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. (Kim MM, Mansfield PF, Das P, Janjan NA, Badgwell BD, Phan AT, Delclos ME, Maru D, Ajani JA, Crane CH, Krishnan S) Int J Radiat Oncol Biol Phys 2008 May 01;71(1):167-72 15 Citations |
| 1 | The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. (Lyu MA, Kurzrock R, Rosenblum MG) Biochem Pharmacol 2008 Feb 15;75(4):836-46 15 Citations |
| 1 | Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. (Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, Wolff RA, Crane CH, Pisters PW) Int J Radiat Oncol Biol Phys 2008 Mar 01;70(3):735-43 64 Citations |
| 1 | Colonic adenocarcinoma in a 13-year-old with cystic fibrosis. (Ibele AR, Koplin SA, Slaughenhoupt BL, Kryger JV, Friedl A, Lund DP) J Pediatr Surg 2007 Oct;42(10):E1-3 12 Citations |
| 1 | Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. (Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, Rotman M, Meredith R, Ang KK) Head Neck 2008 Mar;30(3):281-8 255 Citations |
| 1 | Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. (Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ) J Clin Oncol 2007 Aug 10;25(23):3456-61 382 Citations |
| 1 | Future chemoradiation strategies in pancreatic cancer. (Crane CH, Varadhachary G, Pisters PW, Evans DB, Wolff RA) Semin Oncol 2007 Aug;34(4):335-46 28 Citations |
| 1 | Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. (Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans DB, Wolff RA, Crane CH) Cancer 2007 Jul 01;110(1):47-55 229 Citations |
| 1 | Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. (Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, Thomas J, Ludwig KA, Mantyh CR, Ashton J, Yu D, Hurwitz HI) Int J Radiat Oncol Biol Phys 2007 Jun 01;68(2):472-8 131 Citations |
| 1 | Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. (Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, Delclos ME, Palla S, Guha S, Varadhachary G, Evans DB, Wolff RA, Crane CH) Cancer 2006 Dec 01;107(11):2589-96 75 Citations |
| 1 | Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. (Das P, Wolff RA, Abbruzzese JL, Varadhachary GR, Evans DB, Vauthey JN, Baschnagel A, Delclos ME, Krishnan S, Janjan NA, Crane CH) Radiat Oncol 2006 Oct 24;1:41 20 Citations |
| 1 | Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? (Wong SJ, Machtay M, Li Y) J Clin Oncol 2006 Jun 10;24(17):2653-8 111 Citations |
| 1 | Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. (Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA) Cancer 2006 Jul 01;107(1):83-9 123 Citations |
| 1 | Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. (Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW, Rader JS) Gynecol Oncol 2006 Nov;103(2):489-93 93 Citations |
| 1 | The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. (Crane CH, Varadhachary G, Wolff RA, Pisters PW, Evans DB) Best Pract Res Clin Gastroenterol 2006 Apr;20(2):365-82 43 Citations |
| 1 | Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. (Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA) J Clin Oncol 2006 Mar 01;24(7):1145-51 195 Citations |
| 1 | Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. (Curtis BR, Kaliszewski J, Marques MB, Saif MW, Nabelle L, Blank J, McFarland JG, Aster RH) Am J Hematol 2006 Mar;81(3):193-8 91 Citations |
| 1 | Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. (Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, Mantyh CR, Blobe GC, Honeycutt W, Yu D, Clary BM, Pappas TN, Ludwig KA, Hurwitz HI) J Clin Oncol 2006 Feb 01;24(4):656-62 128 Citations |
| 1 | Development of a method for markerless genetic exchange in Enterococcus faecalis and its use in construction of a srtA mutant. (Kristich CJ, Manias DA, Dunny GM) Appl Environ Microbiol 2005 Oct;71(10):5837-49 50 Citations |
| 1 | A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. (Morgan-Meadows S, Mulkerin D, Berlin JD, Kim K, Bailey H, Saphner T, Jumonville A, Hansen R, Ahuja H, McFarland T, Thomas JP) Oncology 2005;69(2):130-4 15 Citations |
| 1 | Rectal cancer clinical practice guidelines in oncology. (Engstrom PF, Benson AB 3rd, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer Network) J Natl Compr Canc Netw 2005 Jul;3(4):492-508 19 Citations |
| 1 | Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. (Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF, Stoeltzing O, Somcio R, Liu W, Evans DB, Klagsbrun M, Gallick GE, Ellis LM) Br J Cancer 2005 Jul 25;93(2):233-41 97 Citations |
| 1 | Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. (Wong AA, Delclos ME, Wolff RA, Evans DB, Abbruzzese JL, Tamm EP, Xiong HQ, Ho L, Crane CH, Pancreatic Tumor Study Group) Am J Clin Oncol 2005 Jun;28(3):227-33 12 Citations |
| 1 | Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. (Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC) J Clin Oncol 2004 Dec 01;22(23):4762-71 498 Citations |
| 1 | Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. (Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E) J Clin Oncol 2004 Jul 15;22(14):2856-64 157 Citations |
| 1 | Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. (Barber FD, Mavligit G, Kurzrock R) Cancer Treat Rev 2004 Aug;30(5):425-36 37 Citations |
| 1 | A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. (Czito BG, Hong TJ, Cohen DP, Tyler DS, Lee CG, Anscher MS, Ludwig KA, Seigler HF, Mantyh C, Morse MA, Lockhart AC, Petros WP, Honeycutt W, Spector NL, Ertel PJ, Mangum SG, Hurwitz HI) Int J Radiat Oncol Biol Phys 2004 Mar 01;58(3):779-85 7 Citations |
| 1 | Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy. (Morgan-Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G) Invest New Drugs 2002 Nov;20(4):377-82 1 Citation |
| 1 | Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. (Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd) J Clin Oncol 2002 Aug 01;20(15):3270-5 704 Citations |
| 1 | Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? (Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q, Janjan NA) Int J Radiat Oncol Biol Phys 2002 Apr 01;52(5):1293-302 197 Citations |
| 1 | Neoadjuvant strategies for pancreatic cancer. (Evans DB, Wolff RA, Crane CH) Oncology (Williston Park) 2001 Jun;15(6):727-37; discussion 741-4, 747 13 Citations |
| 1 | Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. (Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB) Ann Surg Oncol 2001 Mar;8(2):123-32 315 Citations |
| 1 | Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. (Ochoa L, Hurwitz HI, Wilding G, Cohen D, Thomas JP, Schwartz G, Monroe P, Petros WP, Ertel VP, Hsieh A, Hoffman C, Drengler R, Magnum S, Rowinsky EK) Ann Oncol 2000 Oct;11(10):1313-22 12 Citations |
| 1 | Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. (Evans DB, Wolff RA, Hess KR) Ann Surg 2000 Nov;232(5):727 8 Citations |
| 1 | Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. (Pisters PW, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, Rich TA, Crane CH, Lenzi R, Wolff RA, Abbruzzese JL, Evans DB) J Clin Oncol 2000 Feb;18(4):860-7 80 Citations |
| 1 | Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. (Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, Curley S, Ota DM) J Clin Oncol 1999 Aug;17(8):2403-11 88 Citations |
| 1 | Chemoradiation for localized pancreatic cancer: another perspective. (Evans DB, Abbruzzese JL) Ann Surg Oncol 1999;6(1):4-7 4 Citations |
| 1 | Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. (Evans DB, Pisters PW, Lee JE, Bold RJ, Charnsangavej C, Janjan NA, Wolff RA, Abbruzzese JL) J Hepatobiliary Pancreat Surg 1998;5(3):242-50 42 Citations |
| 1 | Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. (Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, Rich TA, Raijman I, Wolff RA, Lenzi R, Lee JE, Evans DB) J Clin Oncol 1998 Dec;16(12):3843-50 223 Citations |
| 1 | Inconstant association between 27-kDa heat-shock protein (Hsp27) content and doxorubicin resistance in human colon cancer cells. The doxorubicin-protecting effect of Hsp27. (Garrido C, Mehlen P, Fromentin A, Hammann A, Assem M, Arrigo AP, Chauffert B) Eur J Biochem 1996 May 01;237(3):653-9 79 Citations |
| 1 | Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. (Staley CA, Lee JE, Cleary KR, Abbruzzese JL, Fenoglio CJ, Rich TA, Evans DB) Am J Surg 1996 Jan;171(1):118-24; discussion 124-5 223 Citations |
| 1 | Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation. (Evans DB, Abbruzzese JL, Cleary KR, Buchholz DJ, Fenoglio CJ, Collier C, Rich TA) Int J Radiat Oncol Biol Phys 1995 Nov 01;33(4):913-8 32 Citations |
| 1 | Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. (Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ, Ames FC) Arch Surg 1992 Nov;127(11):1335-9 605 Citations |
| 1 | Preoperative chemoradiotherapy for adenocarcinoma of the pancreas. Rationale and technique. (Evans DB, Byrd DR, Mansfield PF) Am J Clin Oncol 1991 Aug;14(4):359-64 16 Citations |
| 1 | Adenocarcinoma of the pancreas: current management of resectable and locally advanced disease. (Evans DB, Rich TA, Byrd DR, Ames FC) South Med J 1991 May;84(5):566-70 24 Citations |
